Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast for Alcohol Use Disorder Treatment in Women and Men
NCT06324435Phase 1Active, not recruiting
- Sponsor
- Yale University
- Start
- May 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apremilast in alcohol use disorder (AUD), sponsored by Yale University. Primary endpoint: Alcohol Consumption at 120 minutes. Started May 2024; status: active, not recruiting.
02
Drugs
apremilast
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT06324435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06324435.